Results 241 to 250 of about 481,186 (302)

Abstracts from the International Pelvic Pain Society (IPPS) Annual Scientific Meeting on Pelvic Pain 2024 in Conjunction with the 6th World Congress on Abdomino-Pelvic Pain. [PDF]

Pain Rep
europepmc   +1 more source

Optimizing vaginal atrophy treatment

Meditsinskiy sovet = Medical Council
Vulvovaginal atrophy (VVA) is considered to be a consequence of estrogen-deficient conditions and disorders of the vaginal microbiocenosis. The disease is most often found in periand postmenopausal age.
A. L. Tikhomirov, V. V. Kazenashev, M. V. Maminova, N. L. Davydenko   +3 more
semanticscholar   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Pharmacotherapy for the treatment of vaginal atrophy

Expert Opinion on Pharmacotherapy, 2019
Introduction: Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer ...
G. Donders, Kateryna Ruban, G. Bellen, S. Grinceviciene   +3 more
semanticscholar   +4 more sources

Treatment of vulvo-vaginal atrophy with hyaluronate-based gel: a randomized controlled study.

Minerva obstetrics and gynecology, 2021
BACKGROUND The study aimed to assess the performance and safety of single-use applicators prefilled with hyaluronic acid (HA)-based vaginal gel (Hyalo Gyn) for the treatment of vulvovaginal atrophy (VVA)-related signs and symptoms in postmenopausal women.
R. Nappi, Miroslav Kotek, A. Brešt'anský, N. Giordan, I. Beriotto, Elisa Tramentozzi   +5 more
semanticscholar   +1 more source

Treatment for vaginal atrophy using microablative fractional CO2 laser: a randomized double-blinded sham-controlled trial.

Menopause, 2020
OBJECTIVE The aim of this study was to evaluate the efficacy of vaginal CO2 laser for the treatment of vaginal atrophy compared to the sham procedure. METHODS Between June 2016 and May 2017, postmenopausal women with moderate to severe intensity of any
Purim Ruanphoo, S. Bunyavejchevin
semanticscholar   +1 more source

Postpartum vaginal atrophy

American Journal of Obstetrics and Gynecology, 1991
Postpartum vaginal atrophy has been briefly noted without adequate clinical description. We present a study of 215 puerperas at a scheduled 4-week postpartum visit, investigating colorpHast vaginal pH, vestibular cotton swab testing, vaginal wall tenderness, and both fixed and wet mount cytologic studies.
P M, Wisniewski, E J, Wilkinson
openaire   +2 more sources

Postmenopausal Vaginal Atrophy and Atrophic Vaginitis

The American Journal of the Medical Sciences, 1997
Menopause is associated with a marked reduction in endogenous estrogen production. Lower levels of circulating blood estrogen have various deleterious effects, including those on the lower urinary tract. The vaginal epithelium becomes atrophied and dry, which can cause vaginal discomfort, itching, and dyspareunia. The epithelium may become inflamed and
L, Pandit, J G, Ouslander
openaire   +2 more sources

Intravaginal Administration of Human Type III Collagen-Derived Biomaterial with High Cell-Adhesion Activity to Treat Vaginal Atrophy in Rats.

ACS Biomaterials Science & Engineering, 2020
Vaginal atrophy (VA) is the thinning and drying of the vaginal walls, which can lead to a variety of symptoms. VA is usually initiated by decreasing estrogen levels in post-menopausal women; so, the traditional treatment of VA is hormone therapy (HT ...
Shuang You, Shuaibing Liu, Xiaojing Dong, Hu Li, Yun Zhu, Lina Hu   +5 more
semanticscholar   +1 more source

Effect of ospemifene on vaginal microbiome in postmenopausal women with vulvovaginal atrophy

Menopause, 2023
This study analyzed the vaginal microbiome profiles in postmenopausal women with and without vulvovaginal atrophy (VVA) and assessed the effect of ospemifene and systemic hormone treatment on the vaginal microbiome of women with VVA.
Stefania Alvisi, C. Ceccarani, C. Foschi, M. Baldassarre, A. Lami, M. Severgnini, T. Camboni, C. Consolandi, R. Seracchioli, M. Meriggiola   +9 more
semanticscholar   +1 more source

Does age at the start of treatment for vaginal atrophy predict response to vaginal estrogen therapy? Post hoc analysis of data from a randomized clinical trial involving 205 women treated with 10 μg estradiol vaginal tablets.

Menopause, 2020
OBJECTIVE Local estrogen therapy (ET) can improve vaginal atrophy symptoms and associated cellular changes in postmenopausal women. This study evaluated whether age at the start of treatment influences response. METHODS This post hoc analysis used data
C. Derzko, S. Röhrich, N. Panay
semanticscholar   +1 more source